Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02311920
Title Temozolomide in Combination With Ipilimumab and/or Nivolumab in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications
Therapies
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
UCSF Medical Center-Parnassus San Francisco California 94143 United States Details
Emory University Hospital/Winship Cancer Institute Atlanta Georgia 30322 United States Details
University of Maryland/Greenebaum Cancer Center Baltimore Maryland 21201 United States Details
National Institutes of Health Clinical Center Bethesda Maryland 20892 United States Details
Dana-Farber Cancer Institute Boston Massachusetts 02215 United States Details
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center New York New York 10032 United States Details
Case Western Reserve University Cleveland Ohio 44106 United States Details
Cleveland Clinic Cancer Center/Fairview Hospital Cleveland Ohio 44111 United States Details
Cleveland Clinic Foundation Cleveland Ohio 44195 United States Details
Ohio State University Comprehensive Cancer Center Columbus Ohio 43210 United States Details
M D Anderson Cancer Center Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field